Lung assist devices developer ALung Technologies Inc said on Thursday that the company's Hemolung Respiratory Assist System (RAS) has treated about 75 COVID-19 patients and has helped these patients recover from COVID pneumonia during the ongoing pandemic.

In the Q2 2020, the company has received the Food and Drug Administration's (FDA) Emergency Use Authorization (EUA) designation for the Hemolung RAS for treating COVID-19 patients. It is the only ECCO2R device currently granted an EUA for the treatment of COVID-19.

The FDA believes the company's Hemolung RAS has the potential to treat lung failure as an adjunct to noninvasive or invasive mechanical ventilation, to reduce hypercapnia and hypercapnic acidosis due to COVID-19 and/or to maintain normalized levels of partial pressure of carbon dioxide (PCO2) and pH in patients suffering from acute, reversible respiratory failure due to COVID-19.

Additionally, the FDA stated the company's Hemolung RAS may provide clinical benefit and that there is no adequate, approved and available alternative to the emergency use of the Hemolung RAS to treat lung failure caused by COVID-19.